Strikingly, PD1d/IL-2v/IL-33 OT1 cells (that is, a 1:1 ratio of PD1d/IL-2v:PD1d/IL-33 cells) induced marked tumor regression and achieved a tumor objective response rate (ORR) of 85.7% (predicted occurrence probability, 83.3%; Extended Data Tables 1 and 2), while the ORR was 0–9% for any other treatment. Here, IL33 is linked to neoplasm.